Evidence dossier - RA Capital Management

GetCoattail manager profile: https://getcoattail.com/manager/ra-capital-management | CIK 0001346824 | Rank #37 of 149 tracked managers by reported 13F value.

Background: Founded: 2002 | HQ: Boston, Massachusetts, United States | Style: Multi-stage healthcare, biotechnology and planetary health investing across public and private markets | Key person: Peter Kolchinsky

Background source: https://en.wikipedia.org/wiki/RA_Capital_Management

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: $11.5B Positions: 84 Top-10 concentration: 60.4% of reported value.

Ticker	Company	Weight	Reported value
ASND	Ascendis Pharma A/S	23.83%	$2.7B
PBLS	Parabilis Medicines Inc	6.88%	$792M
RYTM	Rhythm Pharmaceuticals Inc	6.43%	$740M
PCVX	Vaxcyte Inc	5.80%	$667M
SION	Sionna Therapeutics Inc	3.79%	$436M
TYRA	Tyra Biosciences Inc	3.39%	$390M
EWTX	Edgewise Therapeutics Inc	2.96%	$341M
NAMS	Newamsterdam Pharma Co Nv	2.81%	$324M
COAG	Hemab Therapeutics Holdings	2.49%	$287M
SEPN	Septerna Inc	2.04%	$234M

2. Hypothetical 13F-clone results

WITHHELD for this manager. Price coverage of the disclosed portfolio is too low for a representative clone (latest-filing value coverage and the average unpriced segment weight are stated in section 4): a clone computed from the priced minority would misrepresent the disclosed portfolio. The filing snapshot above and the filing history below are complete as reported.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001144204-16-134325	2016-11-14	30
2016Q4	0001144204-17-009569	2017-02-16	1
2017Q1	0001144204-17-027535	2017-05-15	24
2017Q2	0001144204-17-043212	2017-08-14	22
2017Q3	0001144204-17-059064	2017-11-14	27
2017Q4	0001144204-18-008963	2018-02-14	27

2018Q1	0001144204-18-028896	2018-05-15	31
2018Q2	0001144204-18-044712	2018-08-14	27
2018Q3	0001144204-18-059977	2018-11-14	26
2018Q4	0001144204-19-008235	2019-02-14	25
2019Q1	0001144204-19-026610	2019-05-15	29
2019Q2	0001144204-19-040093	2019-08-14	25
2019Q3	0001104659-19-064263	2019-11-14	32
2019Q4	0001104659-20-021928	2020-02-14	34
2020Q1	0001104659-20-062663	2020-05-15	48
2020Q2	0001104659-20-095562	2020-08-14	57
2020Q3	0001104659-20-125858	2020-11-16	70
2020Q4	0001104659-21-024161	2021-02-16	82
2021Q1	0001104659-21-068149	2021-05-17	82
2021Q2	0001104659-21-106386	2021-08-16	92
2021Q3	0001104659-21-139249	2021-11-15	95
2021Q4	0001104659-22-022807	2022-02-14	97
2022Q1	0001104659-22-061386	2022-05-16	96
2022Q2	0001104659-22-091331	2022-08-15	88
2022Q3	0001104659-22-118654	2022-11-14	81
2022Q4	0001104659-23-021847	2023-02-14	70
2023Q1	0001104659-23-060785	2023-05-15	59
2023Q2	0001104659-23-091405	2023-08-14	54
2023Q3	0001104659-23-118452	2023-11-15	1
2023Q4	0001104659-24-023984	2024-02-14	62
2024Q1	0001104659-24-063050	2024-05-17	1
2024Q2	0001104659-24-089629	2024-08-14	78
2024Q3	0001104659-24-119034	2024-11-14	81
2024Q4	0001104659-25-014181	2025-02-14	89
2025Q1	0001104659-25-049549	2025-05-15	85
2025Q2	0001104659-25-078691	2025-08-14	63
2025Q3	0001104659-25-112469	2025-11-14	67
2025Q4	0001104659-26-016482	2026-02-17	71
2026Q1	0001104659-26-062637	2026-05-15	85
2026Q2	0001104659-26-097251	2026-08-14	84

4. Coverage and adjustments

Price coverage at the latest filing: 66.5% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.